We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | 장 마감 후 (AMC) | $0.85 | — | — | $583.2M | — | 예정 |
| FY2026 Q1 | 2025. 04. 04. | 시각 미정 | — | $-0.98 | — | — | $558.83M | 보고됨 |
| FY2025 Q3 | 2024. 09. 27. | 시각 미정 | — | $-2.23 | — | — | $1.55B |
Consensus PT $43 · 11 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 22. | BTIG | — | 의견 유지 | Buy → Buy | — | BTIG: Buy |
| 2026. 05. 08. | Evercore ISI Group | — | 의견 유지 | Outperform → Outperform | — | Evercore ISI Group: Outperform |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 28. | 시각 미정 | — | $-1.65 | — | — | $1.04B | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
Stored first · Google News · Yahoo Finance (English)
ront Street Bought 384K More Shares of Enovis in Q1. Is ENOV a Buy Now? - AOL.com
ront Street Bought 384K More Shares of Enovis in Q1. Is ENOV a Buy Now? AOL.com
Enovis (ENOV) Earnings Date and Reports 2026 - MarketBeat
Enovis (ENOV) Earnings Date and Reports 2026 MarketBeat
3 Healthcare Stocks That Fall Short
Earnings Preview: Enovis Corp to Report Financial Results Pre-market on May 07 - Moomoo
Earnings Preview: Enovis Corp to Report Financial Results Pre-market on May 07 Moomoo
A Look At Enovis (ENOV) Valuation After ESOP Shelf Registration For Up To 3,650,000 Shares - simplywall.st
A Look At Enovis (ENOV) Valuation After ESOP Shelf Registration For Up To 3,650,000 Shares simplywall.st
ront Street Bought 384K More Shares of Enovis in Q1. Is ENOV a Buy Now?